Our results revealed that BC patients with the MTHFR C677T polymorphism (CT+ TT) exhibited a relatively shorter survival time than 677CC carriers (HR, 1.97; 95% Cl, 1.03–3.77; P = 0.041) (Fig 1). This evidence concerns the gene MTHFR and breast cancer.